- Roche's (OTCQX:RHHBY -0.2%) Ventana Medical Systems and AstraZeneca's (AZN) MedImmune will jointly develop a PD-L1 immunohistochemistry assay to screen patients for MedImmune's clinical trials for MEDI4736, an anti-PDL1 therapy for non-small cell lung cancer. Financial terms are not disclosed.
Ventana and MedImmune collaborate
Recommended For You
More Trending News
About RHHBY Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
RHHBY | - | - |
Roche Holding AG |